Wednesday, July 8, 2026

Patent intelligence · US

US 9737520

Aclidinium for use in improving the quality of sleep in respiratory patients

granted A61KA61K31/439A61K45/06A61K9/0073
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 11
Applicant portfolio 308
Patent details — US 9737520
Jurisdiction
US
Status
granted
Grant date
Aug 22, 2017
Expiration
Aug 17, 2037
Applicant
Almirall, S.A.
Claims
15
CPC classes
A61K, A61K31/439, A61K45/06, A61K9/0073
View on Google Patents ↗

Quick answer

US 9737520 (Aclidinium for use in improving the quality of sleep in respiratory patients) is held by Almirall, S.A.. Status: granted. Granted Aug 22, 2017. Expires Aug 17, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Applicant
Almirall, S.A.
Grant date
Expiration
Claims
15
CPC classes
A61K, A61K31/439, A61K45/06, A61K9/0073, A61K9/0075, A61P

More from Almirall, S.A.

Related pharmaceutical patents in our USPTO index.

  1. US 12421228

    Naphthyridine derivatives as PRC2 inhibitors

    Mirati Therapeutics, Inc. · Expires Sep 18, 2045

    granted
  2. US 12421253

    Tetrahydropyridopyrimidine pan-KRas inhibitors

    Mirati Therapeutics, Inc. · Expires Sep 18, 2045

    granted
  3. US 12414911

    Topical compositions and methods of use

    MIRACLE FRUIT OIL L.L.C. · Expires Sep 11, 2045

    granted
  4. US 12412764

    Substrate-accommodating container

    MIRAIAL CO., LTD. · Expires Sep 4, 2045

    granted
  5. US 12398154

    Azaquinazoline pan-KRas inhibitors

    Mirati Therapeutics, Inc. · Expires Aug 21, 2045

    granted
  6. US 12383503

    Adagrasib solid pharmaceutical compositions

    Mirati Therapeutics, Inc. · Expires Aug 7, 2045

    granted
  7. US 12377101

    Combination therapies

    Mirati Therapeutics, Inc. · Expires Jul 31, 2045

    granted
  8. US 12371435

    Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors

    Mirati Therapeutics, Inc. · Expires Jul 24, 2045

    granted

Frequently asked questions

What is US patent 9737520?

US 9737520 (Aclidinium for use in improving the quality of sleep in respiratory patients) is held by Almirall, S.A.. Status: granted. Granted Aug 22, 2017. Expires Aug 17, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 9737520?

Almirall, S.A. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 308 pharmaceutical patents for this assignee.

When does US 9737520 expire?

Our index shows an expiration date of Aug 17, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.